October 7, 2022
Life Sciences
  • Center for Medicare Director Meena Seshamani said drugmakers who raise prices on medicines for patients with private insurance will still face penalties under the Inflation Reduction Act’s drug pricing law. If drugmakers increase prices faster than the rate of inflation, the policy compels them to refund the difference to the federal government, and Seshamani noted that commercial prices are included in determining the inflation rebate. (Article here)